American Oncology Network, Inc.
AONC
$4.80
$0.000.00%
| Weiss Ratings | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | D | |||
| Rating Factors | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.42 | |||
| Price History | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -11.11% | |||
| 30-Day Total Return | -7.69% | |||
| 60-Day Total Return | 10.34% | |||
| 90-Day Total Return | 54.34% | |||
| Year to Date Total Return | -5.88% | |||
| 1-Year Total Return | -19.84% | |||
| 2-Year Total Return | -52.85% | |||
| 3-Year Total Return | -50.57% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -21.95% | |||
| 52-Week Low % Change | 375.25% | |||
| Price | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.15 | |||
| 52-Week Low Price | $1.01 | |||
| 52-Week Low Price (Date) | Jun 28, 2024 | |||
| 52-Week High Price (Date) | Mar 21, 2024 | |||
| Valuation | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 130.06M | |||
| Enterprise Value | 415.93M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.27 | |||
| Earnings Per Share Growth | 355.23% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.04 | |||
| Price/Book (Q) | -0.62 | |||
| Enterprise Value/Revenue (TTM) | 0.26 | |||
| Price | $4.80 | |||
| Enterprise Value/EBITDA (TTM) | -12.18 | |||
| Enterprise Value/EBIT | -9.52 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 13.26M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -104.88% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 833 886 1725 | |||
| Address | 14543 Global Parkway Fort Myers, FL 33913 | |||
| Website | www.aoncology.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2.74% | |||
| Profit Margin | -0.56% | |||
| Management Effectiveness | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -6.92% | |||
| Return on Equity | -- | |||
| Income Statement | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.58B | |||
| Total Revenue (TTM) | 1.59B | |||
| Revenue Per Share | $120.08 | |||
| Gross Profit (TTM) | 86.65M | |||
| EBITDA (TTM) | -34.16M | |||
| EBIT (TTM) | -43.70M | |||
| Net Income (TTM) | -9.04M | |||
| Net Income Avl. to Common (TTM) | -18.52M | |||
| Total Revenue Growth (Q YOY) | 39.84% | |||
| Earnings Growth (Q YOY) | 90.69% | |||
| EPS Diluted (TTM) | -2.27 | |||
| EPS Diluted Growth (Q YOY) | 68.85% | |||
| Balance Sheet | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 19.43M | |||
| Cash Per Share (Q) | $1.46 | |||
| Total Current Assets (Q) | 271.23M | |||
| Total Preferred Equity (Q) | 64.99 | |||
| Total Equity (Q) | 54.09M | |||
| Current Ratio (Q) | 1.357 | |||
| Book Value Per Share (Q) | -$7.78 | |||
| Total Assets (Q) | 394.81M | |||
| Total Current Liabilities (Q) | 199.86M | |||
| Total Debt (Q) | 147.39M | |||
| Total Liabilities (Q) | 340.72M | |||
| Total Common Equity (Q) | -103.83M | |||
| Cash Flow | AONC - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 3.95M | |||
| Cash from Financing (TTM) | -7.34M | |||
| Net Change in Cash (TTM) | -32.22M | |||
| Levered Free Cash Flow (TTM) | -18.06M | |||
| Cash from Operations (TTM) | -28.83M | |||
